Institute of Pathology.
Division of Nephrology and Immunology.
J Am Soc Nephrol. 2020 Apr;31(4):799-816. doi: 10.1681/ASN.2019080827. Epub 2020 Feb 21.
Hereditary deficiency of adenine phosphoribosyltransferase causes 2,8-dihydroxyadenine (2,8-DHA) nephropathy, a rare condition characterized by formation of 2,8-DHA crystals within renal tubules. Clinical relevance of rodent models of 2,8-DHA crystal nephropathy induced by excessive adenine intake is unknown.
Using animal models and patient kidney biopsies, we assessed the pathogenic sequelae of 2,8-DHA crystal-induced kidney damage. We also used knockout mice to investigate the role of TNF receptors 1 and 2 (TNFR1 and TNFR2), CD44, or alpha2-HS glycoprotein (AHSG), all of which are involved in the pathogenesis of other types of crystal-induced nephropathies.
Adenine-enriched diet in mice induced 2,8-DHA nephropathy, leading to progressive kidney disease, characterized by crystal deposits, tubular injury, inflammation, and fibrosis. Kidney injury depended on crystal size. The smallest crystals were endocytosed by tubular epithelial cells. Crystals of variable size were excreted in urine. Large crystals obstructed whole tubules. Medium-sized crystals induced a particular reparative process that we term . In this process, tubular cells, in coordination with macrophages, overgrew and translocated crystals into the interstitium, restoring the tubular luminal patency; this was followed by degradation of interstitial crystals by granulomatous inflammation. Patients with adenine phosphoribosyltransferase deficiency showed similar histopathological findings regarding crystal morphology, crystal clearance, and renal injury. In mice, deletion of significantly reduced tubular CD44 and annexin two expression, as well as inflammation, thereby ameliorating the disease course. In contrast, genetic deletion of , , or had no effect on the manifestations of 2,8-DHA nephropathy.
Rodent models of the cellular and molecular mechanisms of 2,8-DHA nephropathy and crystal clearance have clinical relevance and offer insight into potential future targets for therapeutic interventions.
腺嘌呤磷酸核糖基转移酶遗传性缺陷可导致 2,8-二羟腺嘌呤(2,8-DHA)肾病,这是一种罕见疾病,其特征是在肾小管内形成 2,8-DHA 晶体。摄入过量腺嘌呤诱导的 2,8-DHA 晶体肾病的啮齿动物模型的临床相关性尚不清楚。
我们使用动物模型和患者的肾脏活检,评估了 2,8-DHA 晶体诱导的肾损伤的发病后果。我们还使用基因敲除小鼠来研究肿瘤坏死因子受体 1 和 2(TNFR1 和 TNFR2)、CD44 或 α2-HS 糖蛋白(AHSG)的作用,这些均与其他类型的晶体诱导性肾病的发病机制有关。
富含腺嘌呤的饮食可诱导小鼠发生 2,8-DHA 肾病,导致进行性肾脏疾病,其特征是晶体沉积、肾小管损伤、炎症和纤维化。肾损伤取决于晶体的大小。最小的晶体被肾小管上皮细胞内吞。不同大小的晶体被排泄到尿液中。大晶体阻塞整个肾小管。中等大小的晶体诱导了一种特殊的修复过程,我们称之为“晶体包裹”。在此过程中,肾小管细胞与巨噬细胞协调,将晶体过度生长并转移到肾间质中,恢复肾小管腔的通畅;随后,通过肉芽炎症降解间质晶体。腺嘌呤磷酸核糖基转移酶缺陷的患者在晶体形态、晶体清除和肾脏损伤方面表现出相似的组织病理学发现。在小鼠中,缺失 显著降低了肾小管 CD44 和膜联蛋白 2 的表达以及炎症反应,从而改善了疾病进程。相比之下, 、 或 的基因缺失对 2,8-DHA 肾病的表现没有影响。
2,8-DHA 肾病和晶体清除的细胞和分子机制的啮齿动物模型具有临床相关性,并为治疗干预的潜在未来靶点提供了深入了解。